Egger’s test provided no evidence for funnel plot asymmetry in the comparison of the SLCO1B1 388 G>A mutation and neonatal hyperbilirubinemia (t = 2.29, p = 0.06). Five case–control studies from three countries, which includes our study, with 637 hyperbilirubinemic case subjects and 918 control subjects, were included in the meta-analysis of the association between the SLCO1B1 521 T>C mutation and neonatal hyperbilirubinemia (Table 4).12, 15, 16, 19 and 20

CP690550 Results of the meta-analysis indicated that there was no statistically significant difference in the risk of neonatal hyperbilirubinemia between SLCO1B1 521 T>C allele carriers (C/C+C/T) and T/T allele carriers (Fig. 4); the same was observed when comparing the T allele to the C allele in the SLCO1B1 521 T>C mutation (Fig. 5). In addition, in the

subgroup analyses based on ethnicity, low risk of neonatal hyperbilirubinemia was found in Chinese neonates, and no significant associations between SLCO1B1 521 T>C allele carriers (C/C+C/T) and T/T allele carriers were found in Brazilian, white, Asian, Thai, and Malaysian neonates; the same was observed when comparing the T allele to the C allele in the SLCO1B1 521 T>C mutation (Table 5). Egger’s test provided no evidence for funnel plot asymmetry in comparisons of SLCO1B1 521 T>C mutations Androgen Receptor Antagonist libraries and neonatal hyperbilirubinemia (comparison of C/C+C/T vs. T/T: t = 0.25, p = 0.82; comparison of T allele vs. C allele: t = 0.40, p = 0.71). Three case–control studies from three countries, with 286 hyperbilirubinemic cases and 456 controls, were included in the meta-analysis of the association between the SLCO1B1 463 C>A mutation and neonatal hyperbilirubinemia (Table 6).15, 17 and 18 see more No carriage of the C to A substitution at

nucleotide 463 was detected in two studies, and only one study,18 which involved American subjects, showed 31 of 153 (20.26%) neonates in the hyperbilirubinemic group (one homozygous and 30 heterozygous) compared to 74 of 299 (24.75%) in the control groups (nine homozygous and 65 heterozygous). In that study18 there were no statistically significant differences in the risk of neonatal hyperbilirubinemia between SLCO1B1 463 C>A allele carriers (A/A+C/A) and C/C allele carriers (OR, 0.77; 95% CI: 0.48–1.23); the same was observed when comparing the A allele to the C allele in the SLCO1B1 463 C>A mutation (OR, 0.72; 95% CI: 0.47–1.11). The present systematic review with meta-analysis indicated that there was no statistically significant difference in the risk of neonatal hyperbilirubinemia in those with the SLCO1B1 388 G>A mutation. In subgroup analyses based on ethnicity, no significant associations were found in white, Asian, Thai, Brazilian, and Malaysian populations, but significant associations were present in Chinese neonates.